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The Use of Nanotrap Particles Technology in Capturing
HIV-1 Virions and Viral Proteins from Infected Cells
Elizabeth Jaworski1., Mohammed Saifuddin1., Gavin Sampey1, Nazly Shafagati1, Rachel Van Duyne1,2,
Sergey Iordanskiy1, Kylene Kehn-Hall1, Lance Liotta3, Emanuel Petricoin, III3, Mary Young4,
Benjamin Lepene5, Fatah Kashanchi1*
1 National Center for Biodefense & Infectious Diseases, George Mason University, Manassas, Virginia, United States of America, 2 Department of Microbiology,
Immunology, and Tropical Medicine, George Washington University, Washington, District of Columbia, United States of America, 3 Center for Applied Proteomics and
Molecular Medicine, George Mason University, Manassas, Virginia, United States of America, 4 Division of Infectious Diseases, Georgetown University, Washington, District
of Columbia, United States of America, 5 Ceres Nanosciences, Manassas, Virginia, United States of America

Abstract
HIV-1 infection results in a chronic but incurable illness since long-term HAART can keep the virus to an undetectable level.
However, discontinuation of therapy rapidly increases viral burden. Moreover, patients under HAART frequently develop
various metabolic disorders and HIV-associated neuronal disease. Today, the main challenge of HIV-1 research is the
elimination of the residual virus in infected individuals. The current HIV-1 diagnostics are largely comprised of serological
and nucleic acid based technologies. Our goal is to integrate the nanotrap technology into a standard research tool that will
allow sensitive detection of HIV-1 infection. This study demonstrates that majority of HIV-1 virions in culture supernatants
and Tat/Nef proteins spiked in culture medium can be captured by nanotrap particles. To determine the binding affinities of
different baits, we incubated target molecules with nanotrap particles at room temperature. After short sequestration,
materials were either eluted or remained attached to nanotrap particles prior to analysis. The unique affinity baits of
nanotrap particles preferentially bound HIV-1 materials while excluded albumin. A high level capture of Tat or Tat peptide
by NT082 and NT084 particles was measured by western blot (WB). Intracellular Nef protein was captured by NT080, while
membrane-associated Nef was captured by NT086 and also detected by WB. Selective capture of HIV-1 particles by NT073
and NT086 was measured by reverse transcriptase assay, while capture of infectious HIV-1 by these nanoparticles was
demonstrated by functional transactivation in TZM-bl cells. We also demonstrated specific capture of HIV-1 particles and
exosomes-containing TAR-RNA in patients’ serum by NT086 and NT082 particles, respectively, using specific qRT-PCR.
Collectively, our data indicate that certain types of nanotrap particles selectively capture specific HIV-1 molecules, and we
propose to use this technology as a platform to enhance HIV-1 detection by concentrating viral proteins and infectious
virions from infected samples.
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caused more deaths than any other single infectious disease [7,8].
As of 2011, an estimated 25 million people have died of acquired
immunodeficiency syndrome (AIDS) caused by HIV-1 infection,
and 34 million are currently living with HIV-1 infection
worldwide; and there is not yet an effective vaccine [7]. Moreover,
2.5 million new infections worldwide and approximately 50,000 in
the United States alone have been reported each year [7,8,9].
Also, a substantial number of newly infected individuals are not
aware of their HIV-1 positive status [8,10,11]. Although long-term

Introduction
Human immunodeficiency virus type 1 (HIV-1) virions possess
9.7 kb dimeric positive-sense single-stranded RNA genome, which
contains a total of nine genes, structural (env, gag, pol), regulatory
(tat, rev) and accessory (nef, vif, vpr, vpu) [1]. HIV-1 transmission
occurs via contact with infected bodily fluids during sexual
intercourse, childbirth, breast-feeding, blood transfusion or intravenous drug use [2,3,4,5,6]. Since its discovery in 1981, HIV-1
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methacrylate (MA) (see Table 1). In some instances, vinyl sulfonic
acid (VSA) monomers can be incorporated into the shell to
improve the ability to exclude high abundance and high molecular
weight analytes. Once the sieving shell is formed, specific organic
baits are covalently attached to the core matrix [38]. The pores of
the shell function to selectively permit the passage of smaller
molecules below a predetermined size and actively exclude high
abundance large proteins such as albumin. Lastly, the high affinity
charge-based bait located in the inner core, dissociates and binds
target molecules through electrostatic and hydrophobic interactions; sequestering them while concurrently preventing degradation [42].
Here, we discuss a novel method by which HIV-1 antigens are
captured and concentrated by nanotrap particles and then
quantitated by standard assays such as western blot, RT assay,
PCR or mass spectrometry. Additional advantages of this
technology include flexibility to multiple buffering conditions
and a short incubation at room temperature. We also demonstrate
the specificity of several nanotrap particles in capturing of HIV-1
virions and individual proteins, including Tat and Nef.

highly active antiretroviral therapy (HAART) can halt the virus
replication in blood to an undetectable level, discontinuation of
therapy rapidly increases virus burden [12,13]. Moreover, patients
under HAART frequently develop various metabolic disorders
and also HIV-associated neuronal disease [14,15,16,17,18].
Today, the main challenge of HIV-1 research is the elimination
of the residual virus in infected individuals [12,13,19].
Tat is an essential regulatory protein that directs efficient
elongation of the HIV-1 genome. It binds to an RNA stem-loop
structure, the trans-activating response element (TAR) at the 59
ends of HIV-1 transcripts, and recruits a positive transcription
elongation complex (P-TEFb) to increase the production of fulllength viral RNA [20,21]. The minimum TAR binding sequence
of Tat has been mapped to a basic domain of 10 amino acids,
comprising mostly Arg and Lys residues, and the regulatory
activity requires the 47 N-terminal residues, which interact with
components of the transcription complex and function as a
transcriptional activation domain [22]. In addition to HIV-1
transcription, active extracellular secretion of Tat has been
reported to influence various cellular genes expression [23,24].
The accessory proteins especially Nef may be dispensable for virus
replication in vitro but essential for HIV-1 pathogenesis in vivo [25].
Nef is a myristoylated protein, localizes to endosomal and plasma
membranes and affects many cellular pathways including cellular
activation, cell survival and apoptosis [26]. Nef has also been
shown to play an active role in modulating immune activation and
long-term maintenance of viral replication in vivo [27].
Current HIV-1 diagnostics are largely based on the presence of
anti-viral antibody in the blood [28,29,30]. Of particular concern
is that elevated viral levels during acute infection contribute to as
much as 26 times more efficient sexual transmission than that of
chronic infection [3,31]. However, due to lack of HIV-specific
antibodies in early acute infection, many of the currently
employed serological diagnostics are not applicable for detection
of the status of HIV-1 infection [32,33,34]. Alternative methods
for detection of early HIV-1 infection rely on the measurement of
viral RNA in blood samples by polymerase chain reaction (PCR)
[35]. While HIV-1 nucleic acid amplification assays are extremely
sensitive and can reliably detect HIV-1 very early in infection, the
fact that the false-positive rates could be as high as 1%, and their
use for routine clinical HIV-1 screening is impeded by their high
cost [33]. Though much of these methods are automated and
designed for high throughput, several other disadvantages include
requirement of trained personnel and complex equipment, and the
propensity for contamination [35,36]. Apart from the above
limitations in regard to early diagnosis of HIV-1 infection, a
number of highly sensitive serological and nucleic acid based
technologies have been developed for both in vivo diagnosis and
laboratory research of HIV-1. Nevertheless, to our knowledge, no
means currently exist to capture, sequester and concentrate HIV-1
virions or proteins.
Our innovative approach employs multifunctional hydrogel
nanotrap particles to capture and enrich a variety of target
molecules from both in vivo and in vitro samples [37]. For example,
several groups have recently utilized these nanotrap particles to
capture various biomarkers including bacterial antigen of Lyme
disease and human growth hormone from urine [38,39]; Bak in
the detection of melanoma as well as components of the
peptidome associated with ovarian and prostate cancer [40,41].
Structurally, these particles are composed of high affinity aromatic
baits containing core surrounded by a sieving shell [38]. Synthesis
of these particles requires polymerization reactions using the
reactants N-isopropyl acrylamide (NIPAm), N,N-Methylenebisacrylamide (Bis) and either allylamine (AA), acrylic acid (AAc) or
PLOS ONE | www.plosone.org

Materials and Methods
Ethics Statement
All research involving human participants have been approved
by The Georgetown University (GTU) Institutional Review Board
(IRB) for The Women’s Interagency HIV Study (WIHS) which
covers viral and immunologic studies related to HIV-1 infection
and its co-morbidities. All the participants provided written
informed consent by signing consent forms to participate in viral
load testing studies under WIHS, and they are on file. All
participants were assigned a unique study number that is used as
identification on all data sheets, stored specimens and laboratory
requests. The participants’ names and contact information are
listed on a separate log that is kept with locator information in a
locked cabinet in a locked room separate from the data file room.
No reports or publications from the WIHS will include any
individuals’ identifying information. This consent procedure was
approved by the GTU IRB for the WIHS study.
All animal works have been conducted according to the US
national guidelines and approved by the George Mason University
Institutional Animal Care and Use Committee.

Cell lines
The uninfected Jurkat and HIV-1 infected J1.1 T-cells obtained
from the NIH AIDS Research and Reference Reagent Program,
were maintained in RPMI-1640 media containing 10% heatinactivated fetal bovine serum (FBS), 1% L-glutamine, and 1%
streptomycin/penicillin (Quality Biological, Gaithersburg, MD). A
HeLa cell derivative TZM-bl cells, expressing CD4, CXCR4 and
CCR5 surface receptors, and with a stably integrated firefly
luciferase reporter gene under the control of an HIV-1 LTR
[43,44], was maintained in DMEM supplemented with 10% FBS,
1% L-glutamine, and 1% streptomycin/penicillin. All cells were
incubated at 37uC in the presence of 5% CO2.

Purified protein samples and antibodies
Full-length HIV-1 Tat protein (aa1-86) was prepared as
described [45]. Briefly, Tat protein was expressed in E. coli.
Bacterial cells were sonicated and clarified by centrifugation before
chromatographed on a Sephacryl S-200 column, and then finally,
purified on a reverse phase HPLC column. Transcriptionally
inactive Tat peptide containing basic domain (aa36–72) [22]
obtained from Peptide Technologies Corporation (Cat# 2369,
2
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Table 1. Structural characteristics of nanotrap particles*.

ID

Core Bait

Matrix

Shell

VSA in Shell

Target

NT073

Cibacron Blue F3GA

NIPAm-Bis-AA

Y

Y

HIV-1 virion, gp41

NT077

Acrylic Acid

NIPAm-Bis-AAc

Y

N

No binding to Tat

NT080

Reactive Red 120

NIPAm-Bis-AA

Y

N

Exosomal TAR-RNA, intracellular Nef, p24

NT081

Cibacron Brilliant Yellow

NIPAm-Bis-AA

Y

N

Minimum binding to Tat

NT082

Cibacron Blue F3GA

NIPAm-Bis-AA

Y

N

Exosomal TAR-RNA, Tat

NT083

Allylamine

NIPAm-Bis-AA

Y

N

Minimum binding to Tat

NT084

Acid Black 48

NIPAm-Bis-AAc

N

N

Tat, p24

NT085

Pigment Red

NIPAm-Bis-AAc

Y

Y

No binding to Tat

NT086

Methacrylate

NIPAm-Bis-MA

Y

Y

HIV-1 virion, membrane-associated Nef, gp41, minimum
binding to Tat

*Nanotrap particles are homogenous hydrogel particles of about 700–800 nm in diameter that have a shell made of polymers of N-isopropylacrylamide (NIPAm) and comonomers such as acrylic acid (AAc), allylamine (AA) and methacrylate (MA) with cross links of N,N’-methylenebisacrylamide (Bis) [37,54]. Some of these shelled
nanotrap particles are also coated with vinyl sulfonic acid (VSA) [38].
doi:10.1371/journal.pone.0096778.t001

and then incubated with target molecule spiked in 100 ml of
appropriate binding buffer for 30 min at room temperature. After
2–3 washes (each 5 min) nanotrap particles containing captured
molecules were resuspended in specific buffer based on the
downstream assays used as described below:
To capture purified proteins, aliquots of Tat36–72 peptide (0.1, 1,
10 mg), full-length Tat (0.1 mg) or gp120 (1 mg) was spiked into
100 ml of FBS-supplemented RPMI and incubated with the slurry
of each nanotrap particles for 30 min at room temperature.
Nanotraps containing each captured molecules were washed in
autoclaved deionized water (200 ml), resuspended in Laemmli
buffer, resolved on SDS-PAGE gel and analyzed by western blot
using anti-Tat antibody or HIV-1 immune serum. In the absence
of purified native Nef, p24 or gp41 protein, HIV-1 infected J1.1
WCE (30 mg) or supernatant was spiked into TNE150 buffer
without detergent and similarly incubated with nanotrap particles
before analyzing elutes by western blot using specific antibodies to
HIV-1 nef, p24 or gp41. To determine whether simpler form of
proteins interacts better with nanotrap particles, Tat protein was
treated with 10 mM DTT for 30 min at 37uC before incubating
with particles.
To capture whole HIV-1 particles, 30 ml slurry of nanotrap
particles was incubated with 1 ml of J1.1 cell supernatants for
30 min at room temperature. Particles were washed by centrifugation (15,000 rpm) for 5 min to remove unbound virus and then
incubated with reverse transcriptase (RT) assay reaction buffer
containing 50 mM Tris–HCl, 1 mM DTT, 5 mM MgCl2,
20 mM KCl, 0.1% Triton, poly(A) (1 U/ml), poly(dT) (1 U/ml)
and [3H]TTP. The mixture was incubated overnight at 37uC, and
10 ml of the reaction mix was spotted on a DEAE Filter mat paper
(PerkinElmer, Shelton, CT, USA), washed four times with 5%
Na2HPO4 and three times with water, and then dried completely.
RT activity was measured in a Betaplate counter (Wallace,
Gaithersburg, MD).
To determine the utility of nanotrap particles for capturing
HIV-1 virions directly from patients’ samples a slurry of nanotrap
particles was incubated in a final volume of 1 ml PBS containing
100 ml serum samples from 4 HAART-treated subjects and 2
uninfected control donors. After incubation at room temperature
for 30 min, the nanotrap particles were washed and the level of
nanotrap particles-bound virus was quantified by qRT-PCR using
primers specific for HIV-1 unspliced RNA as described [46].

Gaithersburg, MD), was tested for initial capture by nine different
nanotrap particles (see Table 1). The molecular weight of this
peptide is 3506.90 Da, and the amino acid sequence comprises of
VCFTTAACSIAAGRKKRRORRRPPOGSQTHQVSLSKO.
The purified T-tropic HIV-1 gp120 protein, HXB120 was
generously provided by Dr. Wen Yuan (University of Virginia).
The monoclonal antibody to HIV-1 p24 (AG3.0) and gp41
(No. 98-6, and 50–69) were obtained through the NIH AIDS
Research and Reference Reagent Program, contributed by Drs.
Jonathan Allan and Susan Zolla-Pazner, respectively. The
monoclonal anti-Nef antibody was obtained through the NIH
AIDS Reagent Program, contributed by Dr. James Hoxie.

Preparation of whole cell extract
Actively growing cells were pelleted, washed twice with PBS
(without Ca2+ and Mg2+) and resuspended in lysis buffer (50 mM
Tris-HCl, pH 7.5; 120 mM NaCl; 5 mM EDTA; 0.5% NP-40;
50 mM NaF; 0.2 mM Na3VO4; 1 mM DTT; and one protease
cocktail tablet/50 ml) before incubating on ice for 20 min with
gentle vortexing. The whole cell extracts (WCE) were centrifuged
at 10,000 rpm for 10 min at 4uC, and protein concentrations were
determined using the Bradford protein assay (Bio-Rad, Hercules,
CA).

Synthesis of nanotrap particles
The nanotrap particles provided by Ceres Nanosciences
(Manassas, VA) were synthesized as previously described
[38,42]. Briefly, the poly-N-isopropylacrylamide (pNIPAm) based
core with incorporated acrylic acid (AAc) was synthesized via
precipitation polymerization, with N’N-methylene bisacrylamide
(BIS) serving as the crosslinker. The core particles were further
functionalized by covalently immobilizing affinity dyes onto the
polymer matrix. For nanotrap particles with a core-shell architecture, the crosslinked pNIPAm-based core is encapsulated within a
crosslinked shell. The crosslinked shell can be inert and consist
only of crosslinked pNIPAm or contain chemical moieties such as
vinyl sulfonic acid (VSA).

Nanotrap particles binding conditions
Each target analyte was captured by nanotrap particles as
described below. Briefly, a 30% slurry (30 ml) of each type of
nanotrap particles was washed twice with specific working buffer
PLOS ONE | www.plosone.org
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isolation by Trizol Reagent (Invitrogen, Carlsbad, CA). Purified
RNA was then converted to cDNA by incubating with Oligo-dT
primers using GoScript Reverse Transcription System (Promega,
Madison, WI). PCR reaction mixtures were prepared using 2 ml of
undiluted, 1021 or 1022 diluted cDNA, 300 nm of each primer:
Gag1483-F
(59-AAGGGGAAGTGACATAGCAG-39)
and
Gag1625-R: (59-GCTGGTAGGGCTATACATTCTTAC-39),
and the iTaq Universal SYBR Green Supermix (Bio-Rad,
Hercules, CA), to amplify 143 nt fragments of HIV-1 gag gene.
Serial dilutions of DNA from 8E5 cells (a CEM-derived cell line
containing a single copy of HIV-1 LAV provirus per cell) were
used as the standards. Quantitative real-time PCR reactions were
then carried out in triplicate using the CFX96 Real-Time PCR
System (BioRad) and SFX Manager Software ver. 2.0.

To capture live HIV-1 by nanotrap particles, J1.1 supernatants
(1, 10, 100 ml) diluted to 1 ml in complete media, were either
untreated or added to 50 ml slurry of NT086 particles before
incubating for one hour with gentle rotation at room temperature.
Nanotrap particles were washed to remove unbound virus by
centrifugation for 10 min and then resuspended in 100 ml of
complete media before adding directly to a monolayer of TZM-bl
cells (56104, 50% confluent) in microtiter plates. The J1.1 cell
supernatants were also incubated with TZM-bl cells without prior
treatment with nanotrap particles. After 48 hrs post incubation at
37uC, cells were lysed and luciferase activity was measured using
BrightGlo Luciferase Assay (Promega) following manufacturer’s
instructions. Luminescence was measured with Promega GloMax
Multi Detection System. Similarly, NT073 nanoparticles were also
used to capture live virus using the above TZM-bl system. After
96 hr post culture, luciferase activity was measured by the
BrightGlo Luciferase Assay as above.

Results
Nanotrap particles capture HIV-1 Tat peptide, full-length
Tat, Nef, and p24

Staining and western blot

To determine the target selectivity for HIV-1 virions or viral
proteins, 9 different hydrogel nanotrap particles (from Ceres
Nanoscience) each containing specific bait such as Cibacron Blue,
Allylamine or Methacrylate, were used in this study (Table 1). One
nanotrap particle (NT084) did not contain the outer shell, and
three of the particles (NT073, NT085 and NT086) contained VSA
incorporated into the shell. The nanotrap particles have submicron dimensions and contain a variety of functional baits in the
core. As shown in Table 1, each nanotrap particle showed specific
selectivity for capturing either whole HIV-1 virion or viral protein.
In order to determine if nanotrap particles could bind HIV-1
proteins, we initially screened all 9 different nanotrap particles for
their ability to captureTat36–72 peptide. This core domain of Tat is
responsible for the binding of TAR-RNA, the RNA regulatory
element within the HIV-1 LTR, and subsequent activation of
transcription of the proviral genome. Structurally, this region is
composed of two domains, a hydrophobic core and a glutaminerich domain, and flanked by cysteine-rich domains [47]. First, we
spiked increasing concentrations of Tat36-72 peptide (0.1–10 mg)
into FBS-supplemented RPMI and then incubated with particle
slurry. A coomassie stain of materials eluted from nanotrap
particles revealed that NT073, NT080, NT082, and NT084
(Fig. 1A, lanes 5–7, 13–15, 21–23, 29–31) successfully captured
Tat36–72 peptide. The nanotrap particles NT077, NT085, and
NT086 failed to capture Tat36–72 peptide (lanes 9–11, 33–35, 37–
39).
To confirm the ability of NT073, NT080, NT082, and NT084
to capture full-length Tat protein, slurry of each nanotrap particle
was incubated with full-length Tat (Fig. 1B). Since NT086 was
unable to capture Tat36–72, we anticipated this particle would fail
to capture the full-length protein. Thus this nanotrap particle
served as our negative control. Western blot analysis revealed that
NT073, NT082 and NT084 successfully captured full length Tat
(Fig. 1B lanes 3, 5 and 6), while NT080 and NT086 (lanes 4 and 6)
recovered Tat, albeit at lower levels. Interestingly, these results
present a discrepancy in the binding of NT086 to Tat36–72 and
full-length Tat. We therefore pre-treated Tat with DTT to reduce
and unfold the protein, and completed the nanotrap particlesmediated pulldown (Fig. 1C). We observed a better recovery in the
binding of the reduced Tat (34%) as compared to the native
protein (11%) by NT086 (Fig. 1C, compare lanes 3 and 4).
However, the overall binding of Tat by this nanotrap particle was
still low.
We then explored the ability of the nanotrap particles to capture
HIV-1 Tat protein from a complex physiologically relevant media.

Materials were eluted from the nanotrap particles in Laemmli
buffer (15 ml), frozen at 220uC for 10 min, heated at 95uC for
5 min, and spun (15,000 rpm) for 5 min. The entire volume was
loaded onto a 4–20% Tris-Glycine gel, run at 200 V, and
transferred onto nitrocellulose membranes. Gels were Coomassie
stained with 40% methanol, 7% glacial acetic acid, and Coomassie
Brilliant Blue (Bio-Rad, R-250). Membranes were blocked with DPBS containing 0.1% Tween-20 and 3% BSA, and incubated
overnight at 4uC with the appropriate primary antibody (a-Tat, aNef, a-p24, a-gp41, a-CD63, a-Alix, or a-Actin). Membranes
were then incubated with the appropriate HRP-conjugated
secondary antibody and developed next day.

Detection of TAR-RNA in nanotrap particles-bound
exosomes by RT-PCR
We have shown previously that exosomes prepared from HIV-1
infected J1.1 cell supernatant contain TAR-RNA [46]. To
determine whether the specific nanotrap particles that efficiently
capture high levels of J1.1 cell-derived HIV-1 could also capture
exosomes that are derived from the J1.1 cell supernatants,
exosomes preparations were similarly incubated with a slurry of
5 different nanotrap particles. After washing, total RNA was
extracted via the addition of Trizol Reagent (Invitrogen) (750 ml)
to the pelleted particles-bound exosome materials. After incubation for 5 min at room temperature, chloroform (200 ml) was
added to the samples and further incubated for 3 min. Samples
were centrifuged (12,0006g) for 15 min at 4uC. To the aqueous
phase, 100% isopropanol (350 ml) was added and centrifuged
(12,0006g) for 10 min at 4uC. The pellet was washed with 75%
ethanol (750 ml) and centrifuged. The RNA pellet was air dried
and reconstituted in 1X TE buffer, heated to 65uC for 10 min and
stored at 220uC. Following RNA extraction, cDNA synthesis was
completed using the iScript Select cDNA Synthesis Kit (Bio-Rad).
The newly synthesized cDNA (10 ml) was amplified by qRT-PCR
using TAR-RNA specific primers [46], and copy numbers of
nanotrap particles-bound TAR-RNA compared.

Quantitation of HIV-1 particles bound per microgram of
nanoparticles
A 100 ml aliquot of the dual-tropic HIV-1 89.1 containing 10 or
1 ng p24/ml in RPMI-1640 medium was incubated with a pellet
of 0.02, 0.2 or 2.0 mg of NT086 nanoparticles for 30 min at room
temperature. The virus bound-nanoparticles were washed three
times with RPMI-1640 by centrifugation, and subjected to RNA
PLOS ONE | www.plosone.org
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Figure 1. Capture of Tat protein by nanotrap particles. (A) Tat36–72 peptide was spiked into RPMI-1640 containing FBS, antibiotics and
glutamine (RPMI+++) at 0.1 mg (lanes 5, 9, 13, 17, 21, 25, 29, 33, 37), 1 mg (lanes 6, 10, 14, 18, 22, 26, 30, 34, 38), and 10 mg (lanes 7, 11, 15, 19, 23, 27,
31, 35, 39). A 30% slurry of nanotrap particles prepared in unsupplemented RPMI was incubated with RPMI containing Tat36–72 for 30 min at room
temperature. Eluted materials (15 ml) were then coomassie stained for the presence of captured Tat peptide. (B) Full-length Tat protein spiked in
RPMI-1640 (+++) (100 ml) was captured by a 30% slurry of each nanotrap particle in unsupplemented RPMI (lanes 3–7), separated on SDS-PAGE and
detected by Western blot using anti-tat antibody. Nanotrap particles incubated with RPMI+++ without Tat were used as background control (lanes 8–
12). (C) Full-length Tat was pre-treated with DTT at 37uC for 30 min (lanes 1 and 3) and incubated with NT086 (lane 3). Percent recovery Tat capture
under reducing conditions was determined from raw densitometry counts of the western blot. (D) Tat protein (1 mg) was spiked into uninfected
patient serum (100 ml), incubated with NT084 (lane 3), and subsequent Tat capture determined by western blot.
doi:10.1371/journal.pone.0096778.g001

ability of functionally native Nef, p24 and gp41 proteins, we
explored the capacity of these particles to capture HIV-1 proteins
from the infected J1.1 cells. The WCE of J1.1 cells (containing
native viral proteins prior to packaging) resuspended into TNE150
buffer without detergent was added to a standard slurry of
nanotrap particles NT073, NT080, NT082, NT084 or NT086.
Materials eluted from each nanotrap particle were analyzed for
the presence of Nef and p24 proteins by western blotting. Our
results demonstrate that NT080 captured the intracellular 30–
40 kDa forms of Nef (Fig. 2A, lane 5), while NT086 captured the
membrane-associated 60 kDa form of Nef (Fig. 2A, lane 8). We
also observed that NT073, NT080, and NT084 bound very low
levels of p24, while NT082 and NT086 completely failed to
capture p24 (Fig. 2, lower panel). The higher binding affinity of
nanotrap particles especially NT086 for membrane-derived Nef
and NT080 for both intracellular Nef and p24 proteins further
suggest a selectivity of nanotrap particles for specific target
molecules.
Previously we were able to influence the binding capability of
NT086 by reducing Tat protein (Fig. 1C). We therefore asked if

We spiked full-length Tat protein into serum collected from an
uninfected donor. Since our previous data indicated that NT084
efficiently captured Tat in cell culture media (Fig. 1A, 1B), we
utilized this nanotrap particle for the pulldown of Tat from serum.
Western blot analysis revealed that NT084 also recovered Tat
efficiently from serum compared to the input (Fig. 1D, compare
lanes 1 and 3). Collectively, our results demonstrate that nanotrap
particles especially NT084 successfully captured HIV-1 Tat
protein from cell culture media as well as complex fluids such as
serum.

Nanotrap particles capture HIV-1 Nef protein more
efficiently than p24 capsid protein
After having explored the binding capabilities of the nanotrap
particles to HIV-1 Tat, we next asked whether these particles
could capture other HIV-1 proteins in their native forms. Since
our previous results indicated that NT073, NT080, NT082,
NT084, and NT086 captured Tat protein, we employed these
nanotrap particles for subsequent experiments. Due to unavail-
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Figure 2. Capture of HIV-1 Nef and p24 capsid proteins by nanotrap particles. Aliquots of infected J1.1 whole cell extract (WCE) (100 mg) in
100 ml of water was incubated with 75 ml of a 30% slurry of nanotrap particles in TNE buffer without detergent for 30 min (lanes 4–8). Nef binding
capacity of each nanotrap particle was subsequently determined by western blot using a-Nef antibody (upper panel). The binding of p24 to nanotrap
particles was also determined by western blot using a-p24 antibody (lower panel). Both Jurkat and J1.1 WCE were used as background controls (lanes
2, 3) without enrichment by nanotrap particles.
doi:10.1371/journal.pone.0096778.g002

treatment. Gp41 specific bands were also observed with NT073
and NT080 captured J1.1 WCE materials. In a repeated
experiment, we also observed better gp41 binding with fresh
antibody in the NT073, NT080 and NT086 captured J1.1
materials (Fig. 3B middle panel). Next, we asked whether NT086
could also interact with gp41 of cell-free HIV-1 in the J1.1
supernatant. As shown in Figure 3B (lower panel), the NT086
particles also bound to gp41 of the cell-free HIV-1 as evidenced by
the right-size band on the western blot when stained with gp41
antibody. Taken together the above data indicate that nanotrap
particles interacted with gp41 suggesting a mechanism of whole
HIV-1 binding via gp41. We then spiked purified gp120 protein
into FBS-supplemented RPMI and conducted the nanotrap
particles pulldown. Following western blotting we observed that
NT073 recovered approximately 25% of the input gp120 material,
however the NT086 failed to capture any gp120 (Fig. 3C) even
though it showed high levels of virus capture by RT assay (Fig. 3A).
Collectively, the interactions between gp41 and the nanotrap
particles especially NT073 and NT086 indicated a potential
mechanism for capturing of intact HIV-1 particles by nanotrap
particles.

the presence of a reducing agent would enhance the binding
affinities of the nanotrap particles for Nef. We incubated J1.1
WCE in the presence of DTT for 30 min at 37uC and then
performed the nanotrap particles pulldown. Our western blot
analysis demonstrated that reducing the samples allowed for the
increased recovery of intracellular Nef by NT073 and NT080 and
membrane-associated Nef by NT082, NT084, and NT086 (data
not shown). Collectively, our results indicate that the nanotrap
particles can be used to enrich both forms of HIV-1 Nef.

Nanotrap particles capture whole HIV-1 virions
Given the variable selectivity of nanotrap particles for binding
multiple HIV-1 proteins, we next asked whether these particles
could capture whole HIV-1 virions. Previously we have shown that
NT053 particles efficiently captured Rift Valley Fever Virus
(RVFV) and also protected the virions from proteolytic degradation [48]. To determine which nanotrap particle captures the
highest level of HIV-1 virus particles, we incubated infected J1.1
cell supernatants with five different particles for 30 min at room
temperature. After washing, the particles-bound HIV-1 virions
were analyzed for RT activity. The results showed that both the
NT073 and NT086 particles equally captured very high levels of
HIV-1 virions, which enriched the RT activity by at least three
times compared to the J1.1 supernatant without prior treatment of
nanotrap particles. Both NT082 and NT084 exhibited a 2-fold
increase in RT activity and NT080 showed the least activity.
Interestingly, NT073 and NT082 nanotrap particles both have the
same Cibacron Blue F3GA bait in the core, while the only
difference is the presence of VSA within the particle shell. As
shown in Figure 3A, NT073 which contains VSA bound almost
double the HIV-1 particles compared to NT082, and hence
implicate a role of the VSA shell in the capture of whole HIV-1
virions.
Because of its size (diameter ,120 nm) HIV-1 virions may not
completely enter into the core through the pores of the shell, we
hypothesized that the nanotrap particles may bind the glycoproteins of the HIV-1 envelope, gp120 or gp41 without requiring the
virions to enter into the particles. We utilized all five different
nanotrap particles to investigate their capturing capacity of gp41.
Standard slurry of each nanoparticle was added to J1.1 WCE, and
assayed for the presence of gp41 by western blot (Fig. 3B upper
panel). A band was observed with J1.1 WCE without nanoparticle
PLOS ONE | www.plosone.org

Captured virions maintain their infectivity
We asked whether the nanotrap particles could capture
infectious HIV-1 particles. Since NT086 captured high levels of
HIV-1 as measured by RT assay, and also bound to viral gp41, we
utilized this particle to capture live HIV-1 from J1.1 culture
supernatants. To assay for transcriptional activation of HIV-1, we
utilized TZM-bl cells, a HeLa cell derivative with a stably
integrated HIV-1 LTR-luciferase. These cells also express CD4
and both co-receptors CXCR4 and CCR5, which permits
infection by both T- and M-tropic viruses [43]. We titrated these
cells with equivalent volumes of the nanotrap pellets pre-treated
with 1, 10 or 100 ml of J1.1 supernatant, and scored for
transcriptional activation measured by luciferase assay. The
unbound virus was removed from the particles by centrifugation
before incubating with TZM-bl cells. Same amounts of J1.1
supernatants were also incubated with TZM-bl cells without prior
treatment to compare the enrichment of HIV-1 binding by
nanotrap particles. As shown in Figure 4A (upper panel),
significantly higher levels of viral transactivation was observed
with nanotrap particles-bound virus when compared with
6
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Figure 3. Capture of HIV-1 virions by nanotrap particles. (A) A 30% slurry of each nanotrap particle in unsupplemented RPMI (30 ml) was
incubated with J1.1 cell supernatants (200 ml) for 30 min at room temperature. Virus-bound nanoparticles were washed to remove unbound virus,
and the nanoparticle pellets were suspended in 50 ml of Tris (250 nM) + 1% Triton X-100, and assayed for RT activity without elution. Fold enrichment
of virus binding to nanotrap particles was analyzed over J1.1 supernatant alone without prior enrichment. (B) HIV-1 gp41 was detected in J1.1 WCE
by WB without nanoparticles pretreatment (upper panel, lane 2). The uninfected Jurkat WCE was used as negative control (lane 3). Binding of HIV-1
by nanotrap particles through interaction with gp41 was detected in J1.1 WCE following treatments with nanoparticles NT073 and NT080 (lanes 4
and 5, respectively). The captures of gp41 from J1.1 WCE were also shown by nanoparticles NT073, NT080 and NT086 but not by NT084 (middle
panel). Fresh antibody was used for this panel. (C) Interaction of nanotrap particles with HIV-1 envelope gp120 was detected by western blot using
anti-HIV human serum. Briefly, purified gp120 glycoprotein (1 mg) or J1.1 culture supernatant was spiked into water and incubated with or without
nanotrap particles slurry for 30 min at room temperature, washed and suspended in Laemmli buffer before resolved on SDS-PAGE gel and analyzed
by western blot.
doi:10.1371/journal.pone.0096778.g003

untreated virus (p,0.01 for 10 ml and p,0.05 for 100 ml) as
measured by luciferase assay. Nanotrap particles alone did not
show luciferase activity above background. Interestingly, in the
same experiment, NT086 particles incubated with up to 20 mg of
pcTat plasmid did not activate HIV-1 transactivation in TZM-bl
cells (data not shown) indicating that DNA alone is neither capable
of binding to nanoparticles and/or activating viral transcription.
Using the same TZM-bl system, the capturing of infectious HIV-1
virions was also shown (Fig. 4A lower panel) by NT073, another
nanotrap particle that bound highest levels of virions previously
measured by RT assay (see Fig. 3A) indicating that certain
nanotrap particles could consistently bind infectious HIV-1
virions. Collectively, these data indicate that nanotrap particles
can significantly enrich for infectious HIV-1 particles potentially
through an interaction with either the surface glycoprotein gp120
or gp41.
In order to validate the selectivity of NT073 and NT086
nanotrap particles for capturing HIV-1 virions, an additional
control experiment was conducted where exosomes preparations
from J1.1 supernatant were incubated with 5 different particles
including the two above. Exosomes were first described by
Harding et al. [49] as cup-shaped nanovesicles (30–100 nm) shed
by a variety of cells. Exosomes usually incorporate certain host
proteins including CD63, CD81, CD9, Alix, TSG101 and heatPLOS ONE | www.plosone.org

shock proteins, and play important roles in intercellular communication, cellular inflammation, antigen presentation and cell
death. Interestingly, the contents of exosomes can be altered by
viral infections, and exosomes can also influence the outcome of
the viral disease [50,51,52,53]. We have recently observed that
naı̈ve cells exposed to HIV-1 exosomes containing miRNA are
more susceptible to infection [46]. Since we have previously shown
that exosomes from the HIV-1 infected J1.1 cells contain TARRNA [46], capturing of exosomes by nanotrap particles was
quantified by analyzing the TAR-RNA copies in the captured
exosomes by qRT-PCR and compared with the binding affinity
for HIV-1 virions. Interestingly, both NT080 and NT082 particles
captured exosomes containing up to 20 million copies of TARRNA while the highest HIV-1 capturing NT073 and NT086
particles bound exosomes at a minimum level (Fig. 4B upper
panel). These data further indicate that the NT073 and NT086
nanotrap particles selectively captured HIV-1 particles.
To further validate the capture of exosomes from HIV-1
infected cell culture supernatant by nanotrap particles NT080 and
NT082, the nanoparticles-bound exosomes materials were lysed in
Laemmli sample buffer and separated on SDS-PAGE gels and
then imunoblotted by antibodies to CD63 and Alix, standard
marker proteins for exosomes. As shown in Figure 4B (lower
panel), both CD63 and Alix were detected only in the NT080 and
7
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Figure 4. Capture of infectious HIV-1 virions by nanotrap particles. (A) HIV-1 infected J1.1 supernatants (1, 10, 100 ml) diluted to 1 ml in
complete media, were either untreated or added to 50 ml of 30% slurry of NT086 nanotrap particles. The particles were incubated for one hour with
gentle rotation at room temperature. The unbound virus was removed by centrifugation for 10 min before incubating the nanotrap particles with
TZM-bl cells at 37uC in microtiter plates. Virus samples were also incubated with TZM-bl cells without prior treatment with nanotrap particles. After
48 hr post incubation, cells were lysed and HIV-1 transactivation analyzed by luciferase assay. The 2 asterices (p,0.01) and 1 asterix (p,0.05)
represent the level of statistical significance between virus captures from 1 and 10 ml, and 10 and 100 ml supernatants, respectively. The NT073
nanoparticles were similarly used to capture infectious virions from J1.1 supernatants and analyzed by TZM-bl system as above (B) Exosomes (15 ml)
collected from J1.1 cell supernatant were spiked into PBS (85 ml) and then incubated with a 30% slurry of five different nanotrap particles (30 ml) for
30 min. Nanotrap particles were washed and subjected to Trizol buffer for total RNA extraction. Evaluation of TAR-RNA contents of exosomes
captured by nanotrap particles was performed via qRT-PCR using specific TAR-RNA primers. The five different nanotrap particles were similarly
incubated with infected J1.1-derived exosomes and washed as in panel B. The nanoparticles-bound exosomes were then suspended in Laemmli
buffer, separated on SDS-PAGE gel and analyzed by western blot using antibody to CD63 and Alix (standard markers for exosomes).
doi:10.1371/journal.pone.0096778.g004

than NT086. As expected when nanoparticles were used to
capture exosomes-containing TAR-RNA from the HIV-1 infected
serum samples (#11 and #12), once again the NT082 selectively
captured exosome particles at levels more than a million-fold
higher than the highest-level HIV-1 capturing NT086 (Fig. 5B
upper panel). These data further indicate that some nanotrap
particles can be used to selectively capture both HIV-1 virions and
exosomes containing TAR-RNA directly from patients’ sera.
In order to further validate the capture of exosomes from HIV-1
infected serum samples (#11 and #12), the nanoparticles-bound
materials were lysed by Laemmli sample buffer, separated on
SDS-PAGE gel and immunoblotted with antibody to exosome
marker proteins CD63 and Alix. Interestingly again, CD63 and
Alix were present only in the serum samples where the TAR-RNA
was detectable by NT082 nanoparticles (Fig. 5B lower panel)
indicating further the selectivity of nanoparticles for virions or
exosomes.

NT082 bound materials while the high level virions capturing
nanoparticles NT073 and NT086 did not capture any exosomes
indicating there is a strong selectivity for capturing virions or
exosomes by nanoparticles.

Capture of virions and exosomes from patients’ sera
We were interested to see whether the nanotrap particles
NT086 that was found to capture HIV-1 virions from cell culture
supernatant at high levels could also selectively capture HIV-1
directly from infected human serum samples. Also, the NT082
particles that captured high levels of exosomes (containing TARRNA) prepared from HIV-1 infected culture supernatant was used
as control to verify the selective affinity of nanotrap particles for
virions or exosomes. As shown in Figure 5A, NT086 selectively
captured HIV-1 virions from two different HAART patients’ sera
(#8 and #10) at a level thousand-fold higher than the NT082 that
was shown to selectively capture exosomes at much higher level

PLOS ONE | www.plosone.org
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Figure 5. Capture of HIV-1 virions and exosomes containing TAR-RNA in patients’ serum by nanotrap particles. Aliquots of serum
samples from 4 HIV-1 infected HAART individuals (#8, #10, #11 and #12) and 2 uninfected donors (#13 and #14) were incubated separately with
nanotrap particles (NT086 and NT082) for 30 min at room temperature. After removing unbound materials by washing, nanotrap particles were
incubated with Trizol buffer for total RNA extraction. The levels of HIV-1 virions and exosomes containing TAR-RNA bound to each type of nanotrap
particles were quantified by qRT-PCR using primers specific to HIV-1 unspliced RNA (A) and TAR-RNA (B). The similarly prepared nanotrap particlesbound serum-derived materials (from samples #11, #12, #13 and #14) were also suspended in Laemmli buffer, separated on SDS-PAGE gel, and
analyzed by western blot using antibody to CD63 and Alix (standard markers for exosomes) (see lower panel).
doi:10.1371/journal.pone.0096778.g005

supernatants by NT086 nanoparticles for both HIV-1 RNA
copies by qRT-PCR and infectious virions by TZM-bl system. As
shown in Figure 6B, the level of viral RNA copies in the J1.1
supernatant were markedly reduced by ART treatment compared
to untreated supernatant, and as expected the NT086 capture
higher amount of HIV-1 virions from untreated samples.
Similarly, the ART treatment entirely eliminated the infectious
virions (Fig. 6C, lanes 3), and thus there was no capture of
infectious virus by NT086 nanoparticle (lane 4). However, the
highest levels of infectious virus was recovered from the
supernatant in the absence of ART (lane 5) while approximately,
20–25% of infectious virus in the J1.1 supernatant was captured by
NT086 nanoparticles (lane 6). We also determined the level of
exosomes capture in the culture supernatants by NT080 following
treatment of infected J1.1 cells with or without ART. As shown in
the Figure 6D, NT080 captured approximately 30% of the total
input of exosomes when compared with no nanoparticles
pretreatment suggesting once again the nanoparticles could more
efficiently capture exosomal RNA in a more diluted sample.

Nanoparticles capacity to bind whole virions and
exosomes
Following establishing the selectivity of certain nanoparticles for
virion capture, we tested the concentration threshold of nanoparticles for maximum capture of HIV-1 virions. Using three different
concentrations of NT086 (0.02, 0.2 and 2.0 mg) and two
concentrations of HIV-1 89.6 virions (16106 and 106106 RNA
copies) in a standard virus capture protocol, it was observed that
the virus binding was directly correlated to the nanoparticles
concentration, and the 2.0 mg nanoparticles (the highest concentration used) captured about 30% of the total input virus (the
highest levels of virus capture) (Fig. 6A). Interestingly, there was
not much difference in virus binding between the two different
virus inputs. Nevertheless, these results suggest that the concentration lower than the 2.0 mg of nanoparticles can be used to
efficiently capture a high percentage of virions from a more diluted
HIV-1 infected samples. In order to mimic the nanoparticles
capture of virions and exosomes from a latently infected sample,
we treated the infected J1.1 cells with an anti-retroviral cocktail
(ART) containing two RT inhibitors and one protease inhibitor for
10 days, before using the supernatants for capture by nanoparticles. The rationale here is that the J1.1 cells normally secret virus
in the supernatant, and in the presence of ART, the level of
extracellular virus is decreased. On the other hand, addition of
20% FBS after removal of ART, will increase the extracellular
virus levels. First, we tested the capture of ART-treated

PLOS ONE | www.plosone.org

Discussion
Given the staggering global estimates for newly acquired HIV-1
infections each year, early detection of infection is of paramount
importance for both successful treatment and prevention of the
disease. In an effort to diagnose HIV-1 infection earlier, novel
detection techniques are continuously being developed and
9
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Figure 6. HIV-1 and exosomes capturing capacity of nanoparticles. (A) 100 ml aliquot of the dual-tropic HIV-1 89.6 containing 10 or 1 ng
p24/ml was incubated with a pellet of 0.02, 0.2 or 2.0 mg of NT086 for 30 min at room temperature. The virus bound-nanoparticles were washed and
RNA isolated. The RNA was converted to cDNA and PCR reaction mixtures were prepared using high-low concentrations of cDNA, Gag primers and
the iTaq Universal SYBR Green Supermix. Serial dilutions of DNA from 8E5 cells were used as the standards. Quantitative real-time PCR reactions were
carried out in triplicate. The asterix represents the statistical significance at the level of p,0.05. (B) The infected J1.1 cells were treated with or
without anti-retrovirals (ART), and then sups were incubated with NT086 to capture virions. After washing, the total RNA was extracted from the
nanoparticle captured materials and then subjected to qRT-PCR using specific primers to unspliced HIV-1 RNA. (C) The infectivity of the nanoparticles
captured virions were also analyzed by incubating them with TZM-bl cells and measuring luciferase activity. The asterix represents the statistical
significance at the level of p,0.05. (D) The NT080 nanoparticles capture of exosomal RNA from J1.1 supernatants with or without pretreatment of
ART were similarly measured by qRT-PCR using specific primers to TAR RNA.
doi:10.1371/journal.pone.0096778.g006

improved upon with the aim of increasing the sensitivity of the
assay as well as reducing the complexity, time and cost. It is also
evident that a growing demand for new technologies has led to the
development of several HIV-1 detection methods with great
promise, particularly for resource limited settings. However, none
of these methods have shown to capture, sequester and
concentrate HIV-1 virions or viral proteins. Furthermore, the
flexibility of new technology to combine with existing assays is
often limited.
In the current manuscript, we employed a novel detection
technology using hydrogel nanotrap particles [54] as a unique
means to concentrate target molecules related to HIV-1 infection.
The advantages of using nanotrap particles include versatility and
selectivity in binding of various target molecules as well as
compatibility to multiple buffering conditions used in standard
PLOS ONE | www.plosone.org

assays including western blot, RT, ELISA, PCR, etc. In addition,
nanotrap particles reactions require a small sample volume (e.g., ,
1 ml) and a short incubation at room temperature (e.g., 30 min)
even though the volume requirement can easily be scaled up if it is
necessary to concentrate target molecules from a large volume of
diluted material. This is consistent to the previous report that
demonstrated successful capture of biomarkers in urine or blood
within 30 min [54]. More importantly, nanoparticle chemistries
can be designed to selectively capture and concentrate small
molecules with low abundance in complex body fluids that are
usually undetectable by the standard assays [37]. Furthermore,
nanotrap particles-captured molecules could be protected from
degradation by proteolysis [37,48]. Thus, the nanotrap particles
technology potentially offers multiple advantages such as rapidity,
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simplicity and high sensitivity over the existing assays of HIV-1
detection.
Our objective was to determine whether the nanotrap particles
could successfully capture HIV-1 virions or proteins in cell culture
media with a long-term goal of capturing specific target molecules
in complex body fluids including human serum, cerebrospinal
fluid, urine, etc. Here we demonstrate that several of the nanotrap
particles (see Table 1) effectively captured HIV-1 proteins,
including the viral transactivator Tat, Nef and gp41. Moreover,
we showed that the capture of each target molecule by nanotrap
particles was selective and can be detectable by standard assay
platforms including western blotting, reverse transcriptase and
PCR. Interestingly, we have demonstrated that the bait Cibacron
Blue in NT082 successfully captured Tat36-72 peptide but was
unable to capture p24 or Nef implicating selectivity of nanotrap
particles for a specific target molecule. Furthermore, the nanotrap
particles NT086 containing the bait Methacrylate bound high
amount of whole HIV-1 particles as well as glycoprotein gp41 and
membrane-associated Nef protein while completely failed to
capture intracellular Nef and p24. Although the precise interaction
between NT086 and HIV-1 virions is yet to be determined, these
data suggest that the bait Methacrylate may have strong selectivity
for HIV-1 glycoprotein or proteins associated with cell membrane.
The selective binding of HIV-1 glycoprotein by the NT086
particles was further supported by the fact that exosomes derived
from the same HIV-1 infected cells were only minimally captured
by the NT086 while they were selectively captured by the NT080
and NT082 particles at high levels. These data further suggest that
even though both HIV-1 and exosomes were derived from the
infected J1.1 cells and likely contained host membrane proteins,
the nanotrap captures were very selective for each target molecule.
More importantly, the nanotrap particles NT086 and NT082
selectively captured HIV-1 virions and exosomes containing TARRNA, respectively, from HAART patients’ serum samples.
The most important finding of this study was that the nanotrap
particles could capture cell-free infectious HIV-1 virions from
infected culture supernatant and that can be efficiently detected in
susceptible TZM-bl reporter cells. In HAART patients similar to
long-term non-progressors (LTNP) or elite suppressors (ES),
plasma virus levels are usually very low (e.g., ,50–1000 copies/
ml of blood) but can be detectable by RT-PCR [55,56,57,58].
However, recovery of infectious virus from these patients in cell
culture could be difficult, expensive and time consuming [19,59].
Our current data suggest that the nanotrap technology could
provide a valuable and cost effective alternative to determine the
infectious status of blood samples from HAART patients, LTNP
or ES.
The nanotrap particles employed in this study were approximately 700–800 nm in diameter, and composed of a porous shell
matrix (approximately 170 nm thick) covalently functionalized
with high affinity bait of approximately 300 nm in diameter core
[37]. The sieving shell of each nanotrap particle serves to restrict
entry of high abundance, high molecular weight carrier proteins
like albumin in serum while allowing entry of low abundance
smaller molecules. The diverse high affinity bait contains bulky
aromatic rings with a variety of functional groups. Thus the baits
function in varying capacities to bind and dissociate the target
molecules from carrier proteins within the sample through
electrostatic and hydrophobic interactions [38,60]. As shown in
a general scheme of nanotrap particles (Fig. 7), although the
mechanism of HIV-1 interaction is not yet clear, smaller viral
proteins (Tat, Nef or gp41) may likely enter through the shell pores
and bind to specific bait while the larger HIV-1 virions (100–
120 nm) may not require entering into the particles to be
PLOS ONE | www.plosone.org

Figure 7. Schematic diagram of a nanotrap particle. The outer
porous shell, inner core and the affinity baits in the core are represented
by yellow, blue and green, respectively. In some nanotrap particles vinyl
sulfonic acid (VSA) is incorporated into the outer shell. The smaller viral
proteins readily enter into the particle core through the pores of the
shell and bind to the specific affinity baits. The larger viral particles do
not completely enter into the core of the nanoparticle, and thus bind to
the outer shell of the particles.
doi:10.1371/journal.pone.0096778.g007

captured. Once captured, the smaller target molecules are
sequestered within the core, and likely be protected from
degradation [48].
Finally, we have identified specific nanotrap particles relevant to
the detection of infectious HIV-1 virions or proteins such as Tat,
Nef or gp41. Also, we have established the working conditions
compatible with downstream assays including TZM-bl cell system,
western blot, RT and qRT-PCR. Currently, a Viral Outgrowth
Assay (VOA) [12] is used to quantify latent reservoirs in PBMCs
from HIV-1 infected HAART patients. This assay involves
purification of resting CD4+T cells from patients’ PBMCs and
then co-cultivation of the purified primary T-cells with the
MOLT-4/CCR5 cell line to allow replication of the latent
provirus that is measured by qRT-PCR specific for HIV-1 RNA.
Our current assay will provide a valuable alternative to the VOA
where nanotrap particles will capture majority of the HIV-1
particles from patient’s serum and allow the detection of the
replicating virus in the reporter TZM-bl cells. Collectively, our
results lend support to the use of nanotrap particles as a reliable
means for capturing and detecting HIV-1 virions and viral
proteins from complex biological fluids in vivo.
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